Dr. Ritho: Medical Cannabis is heavily supervised in treatment and only used with certain symptoms

💊 While claims about strict medical supervision of cannabis use may reflect aspirational regulatory frameworks in some jurisdictions, the evidence base for cannabis in clinical practice remains limited and inconsistent across symptom domains. Current evidence supports potential benefit primarily for chemotherapy-induced nausea, chronic pain, and multiple sclerosis spasticity, though effect sizes are often modest and publication bias may inflate apparent efficacy. Clinicians should recognize that “medical cannabis” encompasses highly variable products with inconsistent cannabinoid ratios and purity, making standardized dosing difficult; additionally, the evidence on long-term safety, drug interactions, and optimal patient selection remains incomplete. Before considering cannabis for any indication, providers should document clear symptom targets, discuss realistic expectations, screen for contraindications including psychiatric vulnerability and substance use history, and ensure robust follow-up to assess both benefit and harms. Practical approach: reserve cannabis discussion for patients with evidence-supported indications who have